Science & Innovation
Unlock the Healing Potential of the Microbiome
Our microbiome consists of billions of microbes most of which are found in our intestine. It sends messages throughout our bodies that are essential for our health and wellbeing.
The microbiome is possibly our most fragile organ, easily disrupted and damaged. A damaged microbiome can lead to common symptoms we have all experienced, such as bloating, diarrhea, or worse, chronic inflammation to name a few.
While there has been a scientific revolution in understanding the microbiome and the role it plays in our daily health, there has been little progress in finding solutions which repair and heal an imbalanced microbiome.
Nature provides a solution to develop and form the microbiome in infants, puppies and kittens through complex glycans found in breast milk. Gnubiotics has been able to mimic nature’s magic and healing abilities to maintain and restore the microbiome.
“There has been little progress in finding solutions which repair and heal an imbalanced microbiome”
Unique diversity of glycans in Gnubiotics products.
A breakthrough in replicating nature’s magic
Gnubiotics was founded to apply a unique scientific understanding that nature is a reservoir of diverse glycans endowed with the potential to restore, renew and repair the microbiome.
We have developed the ability to recreate the unique diversity of glycan structures found in breast milk, nature’s perfect food.
From this foundational understanding, Gnubiotics has applied its proprietary technology to develop a broadening pipeline of product candidates. Our pipeline candidates are designed to mimic the complex glycan structures found in the breast milk of cats, dogs and humans with the goal of forming, maintaining and restoring microbiome health for life.
A unique technology platform
Gnubiotics’ technology platform has excelled beyond product development and analytical capabilities to produce its natural glycan-based products at multi-ton scale. Our first-in-class technology platform is anchored on three pillars:
The Gnubiotics platform enables us to bring an unrivalled source of natural, diverse and scientifically proven glycans into functional microbiome-centric products at industrial scale that target unmet needs in multiple conditions and diseases.
Gnubiotics advances its candidates through an efficient stage-gate pathway that de-risks and optimizes the pipeline. Our pipeline candidates are initially developed under the food regulation that enables a rapid path to first-in-human clinical studies. Therapeutic candidates are then developed further following drug regulations.
Gnubiotics will soon be starting preclinical trials of its first products designed for human therapeutic applications.
- Growth of desirable bacteria
- No growth of pathogens
- Genotoxicity battery
- Sub-chronic study
- Microbiome diversity
- Positive microbial response
- Metabolite production
- Microbiota modulation
- Efficacy markers
- Safety & Tolerability
- Microbiota structure & function
- Efficacy markers
- Evidence of safety, quality and efficacy.
Products & Pipeline Candidates
The desire to enable a precise modulation of the microbiome with specific clinical benefits has stimulated our development of product candidates based on an ensemble of diverse and complex glycans that precisely and safely heal the microbiome.
Our candidates are novel, innovative and uniquely positioned to succeed as they:
- demonstrate utmost precision in their mode of actions by using a natural reservoir of safe, efficacious and extraordinary diverse glycans
- are available at or readily amenable to industrial scale thanks to our established manufacturing capabilities and sustainable supply chain
- target the resident microbiome as opposed to adding foreign bacteria, thus resulting in a safer, more robust modulation.
Scientific publications & References
Our product candidates are supported by scientific publications involving members of the Gnubiotics team and by third-party evidence.
Demonstration of safety, tolerability and utility in feline.
Patrícia M Oba, Anne H Lee, Sara Vidal, Romain Wyss, Yong Miao, Yemi Adesokan, Kelly S Swanson, Effect of a novel animal milk oligosaccharide biosimilar on macronutrient digestibility and gastrointestinal tolerance, fecal metabolites, and fecal microbiota of healthy adult cats, Journal of Animal Science, Volume 99, Issue 1, January 2021, skaa399.
Demonstration of safety, tolerability and utility in canine.
Evaluation of a novel animal milk oligosaccharide biosimilar: Macronutrient digestibility and gastrointestinal tolerance, fecal metabolites, and fecal microbiota of healthy adult dogs and in vitro genotoxicity assays, Anne H Lee, Sara Vidal, Patrícia M Oba, Romain Wyss, Yong Miao, Yemi Adesokan, Kelly S Swanson, Journal of Animal Science, skab014.
Microbiome modulation & detection in humans
High resolution detection of bifidobacteria strains
Dukanovic D, Bazanella M, Kunz JP, Haller D, Adesokan Y. Strain level analysis of BIFIDOBACTERIA in the microbiome of early intervention formula-fed infants in the first year of life. ESPGHAN Annual Conference 2018 (Poster).
Selective microbiome modulation
Ducret V, Perron V, Kunz JP, Steenhout P, Adesokan Y. In vitro consumption and utilization of different Microbiota Accessible Carbohydrates (MACs) by key microbial components of the infant microbiome. ESPGHAN Annual Conference 2018 (Poster).